Nobel winner resigns as head of Columbia institute over Epstein ties

Dr. Richard Axel, a 2004 Nobel laureate in medicine, resigned as co-director of Columbia’s Zuckerman Mind Brain Behavior Institute after the Justice Department’s released Epstein files documented his sustained correspondence with Jeffrey Epstein and visits to Epstein’s Manhattan home (an invitation to Epstein’s Little St. James Island is also noted). Axel, who was not accused of wrongdoing, will remain a Columbia professor but also stepped down as an investigator at the Howard Hughes Medical Institute. The episode presents reputational and governance risk for Columbia and HHMI that could prompt increased donor and oversight scrutiny, though it appears to have limited direct near-term financial impact.

Analysis

Contrarian angles: The market may over-penalize high-quality, revenue-generating spinouts without direct legal exposure — a disciplined screening (market cap $200M–$1B, revenue >$20M, growth >10% YoY) can uncover 10–25% mispricings on headline-driven pullbacks. Historical parallels (donor scandals in academia) show core commercial contracts usually survive; therefore selective buys on >20% post-news dips can be profitable over 6–18 months. Unintended consequence: sustained governance scrutiny could advantage larger pharmas and compliance advisors, so overweighting established large caps is a low-regret trade if headlines persist.

Key Decisions for Investors

• Within 7 trading days, reduce small-cap biotech exposure by 4% of portfolio and redeploy 2% into PFE and 2% into MRK (equal-weight); target hold 6–12 months, trim if either stock underperforms XLV by >5% or individual position drops >10%.
• Buy 3-month XBI 10% OTM puts sized at 1% of portfolio notional as a hedge against headline-driven selloffs; increase hedge by additional 1% if XBI implied volatility breaches 40% or if DOJ releases name >5 new high-profile academic ties within 30 days.
• Initiate a 1% notional pair trade: short XBI and long XLV (Healthcare Select Sector SPDR) for 3 months to capture funding-rotation risk; take profits if spread (XLV performance minus XBI) widens to +3% or close if it narrows to -2%.
• Allocate up to 2% to selective academic spinouts (market cap $200M–$1B, revenue >$20M, YoY revenue growth >10%) that fall >20% post-news, only after confirming no donor/legal exposure in SEC filings; use 25% stop-loss and review fundamentals at 6 and 12 months.
• Monitor DOJ file releases and university press releases daily for 30 days; if >5 additional resignations or if HHMI/Columbia announce material funding withdrawals (>5% of an affected spinout’s revenue), immediately add 1–2% more XBI put hedges within 5 trading days.